3rd International Congress on Stem Cells and Tissue Formation

11-14 July 2010, Dresden, Germany.
3rd International Congress on Stem Cells and Tissue Formation will focus on stem cells including their niches, reprogramming and the formation of tissues of multiple organs, such as the CNS, pancreas, skin, heart and the hematopoietic system. In addition, specifically will be addressed systems biology, biomaterials research (the Max Bergmann Symposium 2010 will be part of the conference, emphasizing biomaterials for stem cell engineering), clinical developments in the area of regenerative medicine and cell-based therapies.

This congress is organized every second year by the Dresden stem cell community, which includes the DFG-Research Center for Regenerative Therapies Dresden (CRTD) and the Collaborative Research Center (SFB 655) "Cells into Tissues".

Scientific Committee

  • Martin Bornhäuser, CRTD
  • Gerhard Ehninger, SFB 655
  • Elisabeth Knust, MPI-CBG
  • Albrecht Müller, SPP 1356
  • Carsten Werner, IPF/MBC + TUD/CRTD
  • Ezio Bonifacio, CRTD
  • Michael Brand, CRTD
  • Frank Buchholz, MPI-CBG
  • Klaus-Peter Günther, Universitätsklinikum Dresden
  • Lorenz Hofbauer, Universitätsklinikum Dresden
  • Wieland Huttner, MPI-CBG
  • Gerd Kempermann, CRTD
  • Günther Lauer, Universitätsklinikum Dresden
  • Michele Solimena, Universitätsklinikum Dresden
  • Alexander Storch, Universitätsklinikum Dresden
  • Ruth Strasser, Universitätsklinikum Dresden
  • Elly Tanaka, CRTD
  • Torsten Tonn, DRK-Blutspendedienst Ost
  • Ingo Roeder, Universität Leipzig
  • Claudia Waskow, CRTD

Call for Abstracts
Abstracts may only be submitted online. All abstracts must be submitted and presented in English language. Each oral or poster abstract should indicate the most appropriate main topic. Due to the anticipated number of excellent abstracts, the organizing committee and the session coordinators reserve the right to reassign abstracts if necessary. All participants are invited to submit abstracts on one of the topics listed below:

  • Mesenchymal and Hematopoietic Stem Cells
  • Neural Stem Cells and Axonal Regeneration
  • Differentiation of Embryonic Stem Cells
  • Stem Cell Niches
  • Spermatogonial Stem Cells
  • Cancer Stem Cells
  • Cardiovascular Stem Cells
  • Islet Cell Regeneration
  • Regeneration of Ectodermal and Endodermal Derivatives
  • Animal Models of Regeneration
  • Tissue Formation supported by Biomaterials
  • Clinical Studies in regenerative Medicine
  • Biology of induced pluripotent stem cells
  • Diabetes

Important dates

  • Online registration: July 05, 2010
  • Deadline for Abstract submission: March 31, 2010
  • Review of abstracts: April 30, 2010
  • Notification about acceptance decisions: May 7, 2010

For further information and registration, please visit:
http://www.stemcellcongress-dresden.org

Most Popular Now

Lilly will supply an additional 150,000 doses of b…

Eli Lilly and Company (NYSE: LLY) announced a modified purchase agreement with the U.S. government to supply an additional 150,000 doses of bebtelovimab for approximately...

Bayer to sell men's health product Nebido™ to Grün…

Bayer and Grünenthal have entered into a definitive agreement regarding the sale of Bayer's men's health product Nebido™ (testosterone undecanoate), for a purchase price ...

Pfizer and BioNTech complete submission to Europea…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced they have completed a submission to the European Medicines Agency (EMA) for an Omicron-adapted biva...

The fourth COVID-19 vaccine reduces the risk of de…

A new study by Tel Aviv University and Ben Gurion University of the Negev, in collaboration with the Israeli Ministry of Health, has found that the fourth COVID-19 vaccin...

Vaccine protection against COVID-19 short-lived, b…

Since COVID-19 vaccines first became available to protect against infection and severe illness, there has been much uncertainty about how long the protection lasts, and w...

AstraZeneca to acquire TeneoTwo and its clinical-s…

AstraZeneca announced an agreement to acquire TeneoTwo, Inc. (TeneoTwo)i, including its Phase I clinical-stage CD19/CD3 T-cell engager, TNB-486, currently under evaluatio...

Demonstration of a potent, universal coronavirus m…

The SARS-CoV-2 that causes COVID-19 has killed 6.3 million people worldwide since 2019, painfully highlighting the vulnerability of humanity to novel coronaviruses. Re...

Research shows investigational drug fosters nerve …

Scientists from the University of Birmingham have shown that a brain-penetrating candidate drug currently in development as a cancer therapy can foster regeneration of da...

NIH launches clinical trial of mRNA Nipah virus va…

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has launched an early-stage clinical trial evaluating an inv...

Anti-inflammatory compound shows potential in trea…

An anti-inflammatory compound may have the potential to treat systemic inflammation and brain injury in patients with severe COVID-19 and significantly reduce their chanc...

Vaccine-induced immune response to omicron wanes s…

Although COVID-19 booster vaccinations in adults elicit high levels of neutralizing antibodies against the Omicron variant of SARS-CoV-2, antibody levels decrease substan...

SARS-CoV-2 hijacks nanotubes between neurons to in…

COVID-19 often leads to neurological symptoms, such as a loss of taste or smell, or cognitive impairments (including memory loss and concentration difficulties), both dur...